EEG Characteristics in ECT

Phase I interventional

Randomized, double Blind

This pilot, randomized parallel study uses direct current EEG to compare infra-slow wave activity in depressed patients receiving ECT with induction by ketamine versus methohexital.

The aim is to identify dcEEG biomarkers of treatment adequacy (infra-slow wave suppression) that could inform ECT dosing and reduce morbidity; outcomes include dcEEG metrics across sessions and clinical depression severity.

University of New Mexico Mental Health Center — Albuquerque, New Mexico, United States

Structured Clinical Interview for DSM-5 will confirm diagnosis of MDD or BPD-depressed (with or without psychotic features);
The clinical indications for ECT including treatment resistance or a need for a rapid and definitive response;
Hamilton Depression Rating Scale 24-item (HDRS-24) > 21;
Age range between 18 and 65 years of age.

Defined neurological or neurodegenerative disorder (e.g., history of head injury with loss of consciousness > 5 minutes, epilepsy, Alzheimer's disease);
Other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, bipolar disorder);
Current drug or alcohol use disorder, except for nicotine and marijuana;
Adults unable to consent, pregnant women, prisoners;
Non-English speakers;
Patients that cannot tolerate Methohexital and Ketamine.

Start: 2019-10-01

End: 2020-10-01

Company

Product

Legal

Detailed Description

Study Arms & Interventions

Methohexital

Interventions

Ketamine

Interventions

Locations

Participants

Inclusion Criteria

Exclusion Criteria

Study Details

Study Team

Sponsors & Collaborators